These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12614299)

  • 1. Review article: pharmacology of esomeprazole and comparisons with omeprazole.
    Dent J
    Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():5-9. PubMed ID: 12614299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of gastric acid with intravenous esomeprazole and omeprazole: results of 3 studies in healthy subjects.
    Röhss K; Wilder-Smith C; Kilhamn J; Fjellman M; Lind T
    Int J Clin Pharmacol Ther; 2007 Jun; 45(6):345-54. PubMed ID: 17595892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    Röhss K; Lind T; Wilder-Smith C
    Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole.
    Andersson T; Röhss K; Bredberg E; Hassan-Alin M
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1563-9. PubMed ID: 11563995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.
    Hunt RH; Armstrong D; Yaghoobi M; James C; Chen Y; Leonard J; Shin JM; Lee E; Tang-Liu D; Sachs G
    Aliment Pharmacol Ther; 2008 Jul; 28(2):187-99. PubMed ID: 18445141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease.
    Röhss K; Hasselgren G; Hedenström H
    Dig Dis Sci; 2002 May; 47(5):954-8. PubMed ID: 12018920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
    Miner P; Katz PO; Chen Y; Sostek M
    Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: gastric acidity--comparison of esomeprazole with other proton pump inhibitors.
    Hatlebakk JG
    Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():10-5; discussion 16-7. PubMed ID: 12614300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months.
    Talley NJ; Lauritsen K; Tunturi-Hihnala H; Lind T; Moum B; Bang C; Schulz T; Omland TM; Delle M; Junghard O
    Aliment Pharmacol Ther; 2001 Mar; 15(3):347-54. PubMed ID: 11207509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [All proton pump inhibitors are equally efficacious in standard dosages].
    Hellström PM; Vitols S
    Lakartidningen; 2003 Jun; 100(25):2212-6. PubMed ID: 12872509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults.
    Pratha VS; Hogan DL; Lane JR; Williams PJ; Burton MS; Lynn RB; Karlstadt RG
    Dig Dis Sci; 2006 Jan; 51(1):123-31. PubMed ID: 16416224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: Esomeprazole--enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion.
    Lindberg P; Keeling D; Fryklund J; Andersson T; Lundborg P; Carlsson E
    Aliment Pharmacol Ther; 2003 Feb; 17(4):481-8. PubMed ID: 12622756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gastroesophageal reflux disease refractory to esomeprazole].
    Velasco MJ; Ortiz V; Ponce J
    Gastroenterol Hepatol; 2005 Feb; 28(2):65-7. PubMed ID: 15710084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving opportunities for effective management of gastro-oesophageal reflux disease.
    Vigneri S; Tonini M; Scarpignato C; Savarino V
    Dig Liver Dis; 2001 Nov; 33(8):720-30. PubMed ID: 11785720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping.
    Miehlke S; Löbe S; Madisch A; Kuhlisch E; Laass M; Grossmann D; Knoth H; Morgner A; Labenz J
    Aliment Pharmacol Ther; 2011 Feb; 33(4):471-6. PubMed ID: 21175704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-response relationship of lansoprazole to gastric acid antisecretory effects.
    Blum RA; Hunt RH; Kidd SL; Shi H; Jennings DE; Greski-Rose PA
    Aliment Pharmacol Ther; 1998 Apr; 12(4):321-7. PubMed ID: 9690720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor.
    Tonini M; Vigneri S; Savarino V; Scarpignato C
    Dig Liver Dis; 2001 Oct; 33(7):600-6. PubMed ID: 11816552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esomeprazole magnesium (Nexium).
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(1):32-41. PubMed ID: 12120118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-secretory and anti-ulcer activities of esomeprazole in comparison with omeprazole in the stomach of rats and rabbits.
    Bastaki SM; Chandranath IS; Singh J
    Mol Cell Biochem; 2008 Feb; 309(1-2):167-75. PubMed ID: 18044010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.